Ani Pharmaceuticals (ANIP) Long-Term Debt Repayments: 2022-2024
Historic Long-Term Debt Repayments for Ani Pharmaceuticals (ANIP) over the last 3 years, with Sep 2024 value amounting to $291.0 million.
- Ani Pharmaceuticals' Long-Term Debt Repayments rose 19500.00% to $291.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $295.5 million, marking a year-over-year increase of 39300.00%. This contributed to the annual value of $3.0 million for FY2023, which is negligibly% changed negligibly from last year.
- As of Q3 2024, Ani Pharmaceuticals' Long-Term Debt Repayments stood at $291.0 million, which was up 38,700.00% from $750,000 recorded in Q2 2024.
- In the past 5 years, Ani Pharmaceuticals' Long-Term Debt Repayments registered a high of $291.0 million during Q3 2024, and its lowest value of -$1.5 million during Q3 2023.
- Its 3-year average for Long-Term Debt Repayments is $27.1 million, with a median of $750,000 in 2024.
- Its Long-Term Debt Repayments has fluctuated over the past 5 years, first slumped by 300.00% in 2023, then skyrocketed by 19,500.00% in 2024.
- Quarterly analysis of 3 years shows Ani Pharmaceuticals' Long-Term Debt Repayments stood at $750,000 in 2022, then skyrocketed by 300.00% to $3.0 million in 2023, then skyrocketed by 19,500.00% to $291.0 million in 2024.
- Its Long-Term Debt Repayments stands at $291.0 million for Q3 2024, versus $750,000 for Q2 2024 and $750,000 for Q1 2024.